Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Targets high-growth eye care expansion push
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
Manoj has over two decades of experience in healthcare operations and biomedical engineering
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
Subscribe To Our Newsletter & Stay Updated
